I don't think there will be a US RNS - to date PYC have not disclosed the name of the pharma as these arrangements are almost certainly subject to NDA. It is unlikely at this early stage that this arrangement makes a significant impact on the pharma and therefore no need to be disclosed. Clearly as time progresses and the results become more significant that will change. In those circumstances the pharma will have an advantage over its competitors in respect of timing but May also be looking for exclusive agreements! SP back to where it was a few weeks ago when similar news announced. I don't expect much more movement upwards until results and income are advised until such time it's likely to drift down again. I have millions of these though and am happy to wait - as I have said all along PYC is only visiting a bag of sweets and it is a punt but with a huge potential upside - but not today or even the next few weeks....
Physiomics Shares Up 34% On "Substantial" Contract With Pharmaceutical Company Wed, 4th Dec 2013 11:18
LONDON (Alliance News) - Shares in Physiomics PLC rose 31% Wednesday morning after it announced that it had signed a "substantial" new contract with a pharmaceutical company for a new programme of studies with its Virtual Tumour platform, a technology that uses a mathematical model used to predict the growth of tumours.
Under the contract the company will begin studies to determine an optimal dosing regime for a new compound under development by the pharmaceutical company. Physiomics will also determine chemotherapy combination partner to maximise the cancer battling effects of the compound.
The company will begin studies immediately, and estimates they will take nine months.
"We are delighted to be working with this global pharma on a new target," said Chief Executive Officer Mark Chadwick in a statement. "This is the second such project we have performed for them using the pre-clinical version of Virtual Tumour and further develops a strong relationship based on positive results."
Shares in Physiomics were trading up 31% at 0.216 pence Wednesday morning
You're exactly right. People spout the usual old nonsense about wait till America opens as if they are barred from buying until their exchange is open. As long as the LSE is open, they can trade. It doesn't matter what the time is.
Case study 2: Single-blind validation study with Lilly As another example, the major pharmaceutical company provided us with data for two drugs (compounds are undisclosed for confidentiality reasons). The data consisted of xenograft growth and biomarker information for the drugs taken individually. We were asked to predict xenograft growth when the two separate drugs were used in two different combinations. Our predictions were then compared against experimental data in a single-blind test.
The Physiomics Virtual Tumour service With the Virtual Tumor, simulations of different drug administrations can be quickly made and the best schedule regimen chosen for in-vivo verification. This technology can be used to: design new regimens with proprietary compounds as well as standard of care, small molecules or biotherapeutical agents; help test possible schedules for combinations of different drugs that would be effectively impossible to investigate experimentally; allow prioritisation of the most effective drug combinations; reduce the number of animals used in studies. Using data that can be gathered during the development of a drug, this could lead to dramatic improvement in its usage, efficacy and prevent loss of synergy due to timing issues.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.